First Tracks Biotherapeutics (NASDAQ:TRAX) Given Buy Rating at HC Wainwright

First Tracks Biotherapeutics (NASDAQ:TRAX)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $57.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 25.88% from the stock’s current price.

A number of other research analysts also recently commented on the stock. UBS Group lifted their price objective on shares of First Tracks Biotherapeutics from $45.00 to $65.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Wells Fargo & Company lifted their price target on First Tracks Biotherapeutics from $30.00 to $55.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. Weiss Ratings assumed coverage on First Tracks Biotherapeutics in a research report on Thursday, August 13th. They set a “sell (d)” rating on the stock. Barclays upped their price objective on First Tracks Biotherapeutics from $48.00 to $65.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Finally, Piper Sandler lifted their target price on First Tracks Biotherapeutics from $54.00 to $95.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, First Tracks Biotherapeutics has an average rating of “Moderate Buy” and a consensus target price of $63.00.

First Tracks Biotherapeutics Trading Up 10.0%

Shares of First Tracks Biotherapeutics stock opened at $45.28 on Thursday. The company has a market cap of $1.62 billion and a PE ratio of -24.61. First Tracks Biotherapeutics has a 12-month low of $14.72 and a 12-month high of $49.91. The business’s 50 day moving average is $37.23.

First Tracks Biotherapeutics (NASDAQ:TRAX) last issued its earnings results on Wednesday, August 12th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.21). Analysts forecast that First Tracks Biotherapeutics will post -4.31 earnings per share for the current fiscal year.

Institutional Trading of First Tracks Biotherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in First Tracks Biotherapeutics in the 2nd quarter valued at about $232,000. Corient Private Wealth LP bought a new stake in shares of First Tracks Biotherapeutics during the second quarter worth approximately $610,000. Wellington Management Group LLP bought a new stake in shares of First Tracks Biotherapeutics during the second quarter worth approximately $1,156,000. Finally, California State Teachers Retirement System acquired a new position in shares of First Tracks Biotherapeutics in the second quarter valued at approximately $10,643,000.

First Tracks Biotherapeutics Company Profile

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.